Tyers Asset Management LLC increased its holdings in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 100.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,212 shares of the medical equipment provider’s stock after buying an additional 1,606 shares during the quarter. Tyers Asset Management LLC’s holdings in Lantheus were worth $91,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in LNTH. Quantamental Technologies LLC purchased a new stake in Lantheus during the 2nd quarter valued at about $56,000. Riverhead Capital Management LLC grew its stake in Lantheus by 100.0% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,600 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 1,800 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Lantheus during the 2nd quarter valued at about $103,000. Aperio Group LLC purchased a new stake in Lantheus during the 2nd quarter valued at about $109,000. Finally, Flinton Capital Management LLC grew its stake in Lantheus by 100.0% during the 2nd quarter. Flinton Capital Management LLC now owns 4,088 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 2,044 shares during the last quarter. Hedge funds and other institutional investors own 95.73% of the company’s stock.

In other news, SVP Michael P. Duffy sold 5,604 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $20.60, for a total value of $115,442.40. Following the sale, the senior vice president now owns 138,890 shares in the company, valued at $2,861,134. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO John J. Bolla sold 1,747 shares of the company’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $27.56, for a total value of $48,147.32. Following the completion of the sale, the chief operating officer now owns 37,155 shares in the company, valued at approximately $1,023,991.80. The disclosure for this sale can be found here. Insiders sold 111,552 shares of company stock worth $2,911,266 in the last 90 days. Company insiders own 2.60% of the company’s stock.

Lantheus stock traded up $0.59 during trading hours on Friday, hitting $24.62. 211,418 shares of the stock traded hands, compared to its average volume of 276,876. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01. The firm’s 50 day moving average price is $22.55 and its 200-day moving average price is $24.74. The stock has a market capitalization of $932.85 million, a price-to-earnings ratio of 26.19, a P/E/G ratio of 2.00 and a beta of 1.50. Lantheus Holdings Inc has a 1 year low of $12.59 and a 1 year high of $29.80.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. The business had revenue of $85.70 million for the quarter, compared to the consensus estimate of $88.72 million. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.25 EPS. Research analysts forecast that Lantheus Holdings Inc will post 1 earnings per share for the current fiscal year.

LNTH has been the topic of several research analyst reports. CJS Securities upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Friday, August 16th. ValuEngine downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub upgraded Lantheus from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Zacks Investment Research downgraded Lantheus from a “hold” rating to a “sell” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $29.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.